IDDI, Biostatistical and eClinical Services for Clinical Trials

Twitter icon
Facebook icon
LinkedIn icon
Google+ icon
YouTube icon
RSS icon

Secondary menu

Home > Resources > Press releases

Press releases

IDDI announces the appointment of Dr .Everardo Saad as Senior Medical Expert

Louvain-la-Neuve, July 01, 2014 – International Drug Development Institute (IDDI), a  corporation based in Belgium with offices in Boston (MA), Houston (TX) and Cupertino (CA) announces the appointment of Dr. Everardo Saad as Senior Medical Expert as of July 2014. Everardo brings over 12 years of experience in Medical Oncology with a special interest in clinical trial designs for stratified oncology and biomarker-based endpoints for a more efficient development of novel therapies for cancer patients.


IDDI increases audit-readiness and simplifies collaboration by switching to Veeva Systems’ Vault eTMF solution

IDDI replaced its mix of a paper-based trial master file (TMF) and e-rooms with Veeva Systems’ cloud-based Vault eTMF solution, part of Veeva’s Development Suite. As a CRO that collects, analyses, and reports all data from international phase I through IV clinical trials for sponsors throughout the US, Europe, and Asia, IDDI wanted a single, centralised system to streamline auditing and collaboration.


IDDI reports successful partnership with Ophthotech

December 5, 2012

IDDI reports successful partnership with Ophthotech in a Phase IIb study showing superior efficacy of Ophthotech's Novel Anti-PDGF Agent FovistaTM combined with Lucentis® over Lucentis® Monotherapy in Wet AMD.


IDDI reports successful partnership with Oraya Therapeutic

May 8, 2012

IDDI reports successful partnership with Oraya Therapeutics for positive INTREPID Study Outcomes With a Non-Invasive Radiation Therapy for Wet AMD


IDDI Reports Partnership with Exonhit

March 28, 2012

IDDI (International Drug Development Institute) Reports Partnership with Exonhit for the clinical validation of diagnostic tests. Louvain-la-Neuve, March 28, 2012 – IDDI (International Drug Development Institute), a corporation based in Belgium, announces its collaboration with Exonhit (Alternext: ALEHT), a French biotechnology company focused on personalized medicine and developing targeted therapeutic and diagnostic products in oncology and Alzheimer’s disease.


IDDI-XClinical : The Best of Two Worlds

March 25, 2011

The IWR/IVR system ID-net™ developed by IDDI now provides an interface to MARVIN, XClinical's EDC System. 


IDDI reports 18% increase of the group revenues

IDDI reports 18% increase of the group revenues and 29% increase of sales for year 2010 compared to year 2009. Damien Tremolet, CEO, comments: "Biopharma companies are eagerly needing advanced and innovative statistical designs (such as adaptive or Bayesian designs) that can be presented to regulatory agencies. IDDI is uniquely positioned to provide such high added value expertise combined with unrivalled biostatistical and eClinical services including randomization and Electronic Data Capture."

Read more


Subscribe to RSS - Press releases